The new generation of cancer medicines raises delicate and potentially explosive issues for the government’s medicines advisory body.

In the past decade, the National Institute for Health and Clinical Excellence has recommended an overwhelming majority of the 251 drugs it has reviewed. More recently, however, Nice has rejected half a dozen cancer therapies and forced the manufacturers of others to develop more imaginative, and cheaper, alternatives.